|
IMP321 IND Allowance in Pancreatic Cancer
Immutep S.A. announced today that the FDA, after review of the Investigational New Drug Application (IND), has allowed the administration of IMP321 in cancer patients in a Phase I trial conducted by Dr. William G. Hawkins at the Washington University School of Medicine in Saint Louis (MO).Published 10/2008 by admin@immutep.com © 2002 Immutep, S.A.
|
Press Release
05/2010 - Immutep Announces Oral Presentation at ASCO Annual Meeting of IMP321 Final Results In Phase I/II Chemoimmunotherapy Trial
Immutep S.A. announced today that the final results from its Phase ...
01/2010 - ImmuFact IMP321 doubles clinical response rate in first-line metastatic breast cancer 
Immutep S.A. announced today the final results from its Phase I/II ...
10/2009 - New results confirm that ImmuFact IMP321 doubles clinical response rate 
Immutep S.A. announced today interim results from the first three ...
09/2009 - Clinical research paper describes IMP321’s potency in inducing progression-free survival improvement and effector memory T cells 
Immutep S.A. announced today the publication of a clinical research ...
04/2009 - A Phase I clinical trial of ImmuFact IMP321 in pancreatic cancer has started at Washington University in Saint Louis (MO) 
Immutep S.A. announced today the first administration of IMP321 in ...
|
||||||||||||||||
